MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that Aetna has updated its TMS (transcranial magnetic stimulation) coverage to include adolescents aged 15 and older with MDD (major depressive disorder). This expanded access follows the recent clearance from the U.S. Food and Drug Administration (F ...

MALVERN, Pa., July 11, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that California Medicaid (Medi-Cal) has added TMS (transcranial magnetic stimulation) coverage for adults and adolescents aged 15 and older with MDD (major depressive disorder). This is the first policy from Medi-Cal that includes TMS, and the access ...

MALVERN, Pa., July 11, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that California Medicaid (Medi-Cal) has added TMS (transcranial magnetic stimulation) coverage for adults and adolescents aged 15 and older with MDD (major depressive disorder). This is the first policy from Medi-Cal that includes TMS, and the acces ...

MALVERN, Pa., July 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that updated policies from BlueCross BlueShield (BCBS) of Michigan and Cambia Health Solutions will broaden access to TMS (transcranial magnetic stimulation) by expanding the eligible age range to 15 years and older. These health policy updates come ...

MALVERN, Pa., July 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that updated policies from BlueCross BlueShield (BCBS) of Michigan and Cambia Health Solutions will broaden access to TMS (transcranial magnetic stimulation) by expanding the eligible age range to 15 years and older. These health policy updates come ...

Neuronetics, Inc. (STIM) recently announced the nationwide launch of the Better Me Provider (BMP) program. The BMP program will be a part of the company’s NeuroStar product line. The providers participating in the program are expected to maintain correct standards, developed in collaboration with a network of transcranial magnetic stimulation (TMS) medical experts.The latest development will help Neuronetics meet new standards and improve treatment accessibility within the mental health industry.About BMP P ...

文章核心观点 - 公司推出了"Better Me Provider (BMP)"计划,旨在提高精神健康行业的患者护理和响应能力,为患者提供更优质的治疗体验 [1][2][5] - 该计划在试运行阶段取得了显著成功,包括大幅提高了响应时间、提升了医生的培训水平、加快了患者的参与过程 [2][3][4] - 该计划现已全国推出,目前已有300家活跃网点参与,未来还将有更多网点加入 [6][7] 公司概况 - 公司专注于设计、开发和销售改善患者神经健康障碍生活质量的产品 [1] - 公司的主要产品是NeuroStar先进治疗系统,是目前治疗成人抑郁症的主要经颅磁刺激(TMS)疗法,已经完成了超过640万次治疗 [11] - 该系统还获得FDA批准用于治疗强迫症和15-21岁青少年抑郁症 [11] 计划详情 - "Better Me Provider"计划是公司与TMS医疗专家合作制定的一项全面的商业计划 [7] - 参与该计划的医疗机构需满足一系列严格的患者护理和响应标准,包括仅使用NeuroStar系统、参加NeuroStar培训、确保快速响应时间等 [7] - 该计划旨在提高患者的治疗可及性,让更多需要帮助的人获得潜在的生命改变性治疗 [2]

文章核心观点 公司推出了"Better Me Provider"(BMP)计划,旨在提高精神健康行业的患者护理和响应能力,为患者提供更优质的治疗体验 [1][2][5] 关于BMP计划 1) BMP计划是一项全面的商业计划,与TMS医疗专家合作制定了严格的标准,包括:专门使用NeuroStar治疗、参加NeuroStar University培训、确保及时响应、建议患者完成全程治疗、优化网站和社交媒体内容等 [7] 2) 在试点阶段,BMP计划显示了显著成功,大幅提高了提供者的效率和响应能力,从而改善了NeuroStar患者的体验 [2] 3) 参与BMP计划的诊所将获得公司的支持,帮助他们满足入选标准并加入该计划 [6] 患者体验改善 1) 参与BMP计划的诊所将响应时间提高了6.4倍,大幅缩短了从初次咨询到运动阈值测定的时间,使得3.6倍更多的患者接受了治疗 [2][4] 2) 通过NeuroStar University的高级培训,参与者平均能治疗58%更多的患者 [3] 公司概况 1) 公司致力于设计、开发和销售改善患者生活质量的神经健康产品,其NeuroStar高级治疗是目前治疗成人抑郁症的主要TMS疗法 [11] 2) NeuroStar治疗可以改善抑郁症和焦虑症状,并获批用于治疗强迫症和青少年抑郁症 [11]

MALVERN, Pa., June 13, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the 12th Annual Meeting of the Clinical TMS Society (CTMSS) in London, England from June 13th-15th. Six posters and one oral presentation will feature data generated utilizing the NeuroStar TMS (transcranial magnetic stim ...

MALVERN, Pa., June 13, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the 12th Annual Meeting of the Clinical TMS Society (CTMSS) in London, England from June 13th-15th. Six posters and one oral presentation will feature data generated utilizing the NeuroStar TMS (transcranial magnetic sti ...